Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 823 matching drugs for TUBB — including drugs targeting any of its 67 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
vinorelbine, cisplatin, vinorelbine, cisplatin, radiotherapy TUBB Direct 2
concomitant temozolomide (tmz), radiotherapy, procarbazine, adjuvant temozolomide (tmz), ccnu, vincristine TUBB Direct 1
dabrafenib, trametinib, carboplatin, vincristine TUBB Direct 1
depatuxizumab mafodotin, temozolomide, lomustine TUBB Direct 1
disulfiram, copper, alkylating agents TUBB Direct 1
docetaxel, cisplatin, radiation, surgery, vinorelbine, cisplatin TUBB Direct 1
gemcitabine, vinorelbine, cisplatin, etoposide, carboplatin TUBB Direct 1
mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan TUBB Direct 1
patupilone TUBB Direct 1
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine TUBB Direct 1
temozolomide, depatuxizumab mafodotin, radiation, placebo for abt-414 TUBB Direct 1
trametinib, vinblastine TUBB Direct 1
vinorelbine TUBB Direct yes 1
vinorelbine, xr9576 TUBB Direct 1
belantamab mafodotin TUBB Direct yes 0
cabazitaxel TUBB Direct yes 0
docetaxel TUBB Direct yes 0
eribulin TUBB Direct yes 0
eribulin mesylate TUBB Direct yes 0
vinblastine TUBB Direct yes 0
vinblastine sulfate TUBB Direct yes 0
vincristine TUBB Direct yes 0
vincristine sulfate TUBB Direct yes 0
vindesine TUBB Direct yes 0
vindesine sulfate TUBB Direct yes 0
vinflunine TUBB Direct yes 0
vinorelbine tartrate TUBB Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
olaparib PARP2 SSL via PARP2 yes 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib KDR SSL via KDR yes 5
docetaxel, thalidomide BCL2 SSL via BCL2 4
docetaxel, thalidomide TUBB1 SSL via TUBB1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TUBB1 SSL via TUBB1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR1 SSL via FGFR1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR3 SSL via FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
amg 193, docetaxel, comparator amg 193 test tablet BCL2 SSL via BCL2 3
amg 193, docetaxel, comparator amg 193 test tablet TUBB1 SSL via TUBB1 3
bms-986340, bms-936558-01, docetaxel BCL2 SSL via BCL2 3
bms-986340, bms-936558-01, docetaxel TUBB1 SSL via TUBB1 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR1 SSL via FGFR1 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR3 SSL via FGFR3 3
pembrolizumab, belzutifan, lenvatinib FGFR1 SSL via FGFR1 3
pembrolizumab, belzutifan, lenvatinib FGFR3 SSL via FGFR3 3
pembrolizumab, belzutifan, lenvatinib KDR SSL via KDR 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BCL2 SSL via BCL2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR1 SSL via FGFR1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR3 SSL via FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TUBB1 SSL via TUBB1 2
alvocidib, paclitaxel BCL2 SSL via BCL2 2
alvocidib, paclitaxel CDK1 SSL via CDK1 2
alvocidib, paclitaxel TUBB1 SSL via TUBB1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BCL2 SSL via BCL2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan KDR SSL via KDR 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TUBB1 SSL via TUBB1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 KDR SSL via KDR 2
bbi-355, erlotinib, futibatinib FGFR1 SSL via FGFR1 2
bbi-355, erlotinib, futibatinib FGFR3 SSL via FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
bryostatin 1, paclitaxel BCL2 SSL via BCL2 2
bryostatin 1, paclitaxel TUBB1 SSL via TUBB1 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin BCL2 SSL via BCL2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin TUBB1 SSL via TUBB1 2
cabazitaxel TUBB1 SSL via TUBB1 2
cabozantinib KDR SSL via KDR yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDR SSL via KDR 2
capecitabine, docetaxel BCL2 SSL via BCL2 2
capecitabine, docetaxel TUBB1 SSL via TUBB1 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy BCL2 SSL via BCL2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy TUBB1 SSL via TUBB1 2
carboplatin, docetaxel BCL2 SSL via BCL2 2
carboplatin, docetaxel TUBB1 SSL via TUBB1 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection BCL2 SSL via BCL2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection TUBB1 SSL via TUBB1 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu BCL2 SSL via BCL2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu TUBB1 SSL via TUBB1 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy BCL2 SSL via BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TUBB1 SSL via TUBB1 2
carboplatin, paclitaxel, panitumumab, radiotherapy BCL2 SSL via BCL2 2
carboplatin, paclitaxel, panitumumab, radiotherapy TUBB1 SSL via TUBB1 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 BCL2 SSL via BCL2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 TUBB1 SSL via TUBB1 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy BCL2 SSL via BCL2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy TUBB1 SSL via TUBB1 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy BCL2 SSL via BCL2 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.